Valkema MJ, Noordman BJ, Wijnhoven BPL, et al. - In this side study of the prospective diagnostic pre-SANO trial, researchers prospectively examined the optimal evaluation of qualitative and quantitative ¹⁸F-FDG PET/CT in response assessments 12–14 wk following neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer individuals. In total, 129 of 219 people were examined. Qualitative and quantitative analyses of ¹⁸F-FDG PET/CT were unable to correctly identify tumor regression grade 3–4 and to differentiate substantial residual disease from benign inflammation-induced ¹⁸F-FDG uptake following nCRT. Nevertheless, for the identification of interval metastases, ¹⁸F-FDG PET/CT is beneficial and it might become beneficial in an active surveillance approach with serial ¹⁸F-FDG PET/CT scanning.